Literature DB >> 3860275

Clinical sub-groups of multiple sclerosis in relation to HLA: DR alleles as possible markers of disease progression.

P Duquette, F Décary, J Pleines, D Boivin, G Lamoureux, J B Cosgrove, Y Lapierre.   

Abstract

We have examined the distribution of HLA antigens in 70 multiple sclerosis (MS) patients divided in three groups defined according to clinical criteria: benign MS, severe MS, cerebellar MS. We have found a significant association between severe MS and HLA-DR2, and between benign MS of more than 15 years of evolution and HLA-DR3. We review previous work along the same line and conclude that the association of HLA antigens with "clinical subgroups of MS" could indicate a genetically based heterogeneity of the disease and offer help in establishing a prognosis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3860275     DOI: 10.1017/s0317167100046795

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  6 in total

1.  HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis.

Authors:  A E Hensiek; S J Sawcer; R Feakes; J Deans; A Mander; E Akesson; R Roxburgh; F Coraddu; S Smith; D A S Compston
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-02       Impact factor: 10.154

2.  HLA and prognosis in multiple sclerosis.

Authors:  B Runmarker; T Martinsson; J Wahlström; O Andersen
Journal:  J Neurol       Date:  1994-05       Impact factor: 4.849

3.  Expression of the human histocompatibility leukocyte antigen DR3 transgene reduces the severity of demyelination in a murine model of multiple sclerosis.

Authors:  K M Drescher; L T Nguyen; V Taneja; M J Coenen; J L Leibowitz; G Strauss; G J Hammerling; C S David; M Rodriguez
Journal:  J Clin Invest       Date:  1998-04-15       Impact factor: 14.808

4.  HLA-DQ polymorphism influences progression of demyelination and neurologic deficits in a viral model of multiple sclerosis.

Authors:  K D Pavelko; K M Drescher; D B McGavern; C S David; M Rodriguez
Journal:  Mol Cell Neurosci       Date:  2000-06       Impact factor: 4.314

5.  Influence of histocompatibility genes on disease susceptibility and treatment response in patients with relapsing-remitting multiple sclerosis treated with interferon β-1a.

Authors:  Shlomo Flechter; Tirza Klein; Lea Pollak
Journal:  Neurol Int       Date:  2011-06-15

Review 6.  Multiple sclerosis: basic concepts and hypothesis.

Authors:  M Rodriguez
Journal:  Mayo Clin Proc       Date:  1989-05       Impact factor: 7.616

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.